FCs and CAR Ts teamwork makes the dreamwork

Chimeric antigen receptor (CAR) T-cell therapy has recently been a huge topic in cancer immunotherapy, however the effect on solid state tumors remains limited due to poor tumor infiltration and persistence. This review is of a study by sun. et al "Dendritic cell/tumor fusion cell vaccine combined with EGFRvIII-specific nanobody CAR T cells enhances antitumor efficacy against glioblastoma."; this study uses nanobody-based CAR T cells (Nb-CAR Ts), that camelid-derived single-domain antibodies to reduce steric hindrance, which has been shown to improve tumor penetration when compared to traditional CAR receptors. They used EGFRvIII-specific Nb-CAR Ts along with a dendritic cell/tumor fusion cell (FC) to target glioblastoma. EGFRvIII Nb-CAR Ts demonstrated enhanced proliferation, activation, cytokine production, and antigen-specific cytotoxicity in vitro. Key tests showed the effectiveness of the NB CarT cell alone when compared to control groups-- both in vivo and in vitro. NB CarT cell + FC had improved outcomes, both in vivo and in vitro when compared to NB CarT cell alone, FC alone, or NB CarT cell with non fusion dendritic cell. This study shows a promsing method of treating solid state tumors.